Tolnaftate

Tolnaftate

SCHEMBL29484221

Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 1.00
MAPT P10636 4/20 1.00
TDP1 Q9NUW8 3/20 1.00
NR1I2 O75469 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C9 P11712 1/20 1.00
MAPK1 P28482 1/20 1.00
CYP2C19 P33261 1/20 1.00
HTR2B P41595 1/20 1.00
CYP51A1 Q16850 1/20 1.00
HSD17B1 P14061 3/20 0.45
HSD17B2 P37059 3/20 0.45
SIGMAR1 Q99720 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 2/20 0.41
ESR1 P03372 1/20 0.41
CYP2A6 P11509 2/20 0.40
MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tolnaftate SCHEMBL8160019 1.00 LMNA (1.00) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL30382951 1.00 LMNA (1.00) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL3520 1.00 LMNA (1.00) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL10897084 0.99 LMNA (0.97) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL22227756 0.99 LMNA (0.97) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL28341077 0.99 LMNA (0.97) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL8985002 0.95 LMNA (0.90) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL8609283 0.94 LMNA (0.88) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL15568032 0.94 MAPT (0.88) LMNAMAPTTDP1NR1I2CYP1A2
Tolnaftate SCHEMBL893162 0.94 LMNA (0.88) LMNAMAPTTDP1NR1I2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
EP-3876949-B1 DERMAL SKIN PROTECTANT AND CARRIER INSPIRED MAT STRATEGIES LLC (US) 2025-08-20 EP claimed
EP-4069690-B1 POLYMORPHS OF TRIAZOLE ANTIFUNGAL COMPOUND PC945 PULMOCIDE LTD (GB) 2024-11-13 EP claimed
EP-3529359-B1 TUMOR INFILTRATING LYMPHOCYTES FOR USE IN THERAPY UNIV MINNESOTA (US) 2023-12-13 EP claimed
EP-2916820-B1 DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS ROCHAL TECH LLC (US) 2023-10-11 EP claimed
EP-3139939-B1 COMPOSITIONS AND METHODS FOR TREATING SKIN AND MUCOUS MEMBRANE DISEASES UNIV CALIFORNIA (US) 2023-09-06 EP claimed
EP-2640393-B1 CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS UNIV SOUTHERN CALIFORNIA (US) 2022-10-12 EP claimed
US-12508252-B2 Compositions and methods for pain relief and numbing RELIEVE THERAPEUTICS PTE. LTD. (SG) 2025-12-30 US disclosed
US-12478747-B2 Aerosol delivery device and operating method for the aerosol delivery device PARI PHARMA GMBH (DE) 2025-11-25 US disclosed
EP-4631628-A2 AEROSOL GENERATOR PARI Pharma GmbH (DE) 2025-10-15 EP disclosed
EP-4230243-B1 METHOD OF MANUFACTURING A VIBRATABLE MEMBRANE FOR USE IN AN AEROSOL GENERATOR PARI PHARMA GMBH (DE) 2025-10-01 EP disclosed
US-12151033-B2 Foam compositions, foam matrices and methods COVALON TECHNOLOGIES INC. (CA) 2024-11-26 US disclosed
EP-4438088-A2 AEROSOL DELIVERY DEVICE AND OPERATING METHOD FOR THE AEROSOL DELIVERY DEVICE PARI Pharma GmbH (DE) 2024-10-02 EP disclosed
EP-2968680-B1 SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION C P MEDICAL CORP (US) 2023-05-03 EP disclosed
US-20230119086-A1 AEROSOL DELIVERY DEVICE AND OPERATING METHOD FOR THE AEROSOL DELIVERY DEVICE PARI PHARMA GMBH (DE) 2023-04-20 US disclosed
US-11596710-B2 Biocompatible hydrogel treatments for retinal detachment AQUARIAN CREDIT FUNDING LLC 2023-03-07 US disclosed
US-11547822-B2 Aerosol delivery device and operating method for the aerosol delivery device PARI PHARMA GMBH (DE) 2023-01-10 US disclosed
EP-4093812-A1 BIODEGRADABLE COMPOSITIONS AND ARTICLES MADE FROM CELLULOSE ACETATE Eastman Chemical Company (US) 2022-11-30 EP disclosed
US-20220160689-A1 COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING Ziropa, Inc. (US) 2022-05-26 US disclosed
US-20220088630-A1 AEROSOL GENERATOR PARI PHARMA GMBH (DE) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12508252-B2 Compositions and methods for pain relief and numbing PRPH, PMP22, RBM25 LMNA 760/4885MAPT 274/4885TDP1 384/4885
US-11596710-B2 Biocompatible hydrogel treatments for retinal detachment ALDH1A2, RB1, UACA LMNA 615/4885MAPT 3051/4885TDP1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.